Slingshot members are tracking this event:

Keryx (KERX) Plans to Submit FDA Application in Q3 to Expand Indication for Auryxia to Include the Treatment of Iron Deficiency Anemia in Adults With Stage 3-5 Non-Dialysis-Dependent Chronic Kidney Disease

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 12, 2017
Occurred Source:
Related Keywords Expanded Indication, Auryxia, Q3, Iron Deficiency Anemia, Stage 3-5, Non-dialysis-dependent, Chronic Kidney Disease, Fda Application